By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Waters today reported a 13 percent spike in third-quarter revenues, but reduced its earnings guidance for full-year 2011.

For the three months ended Oct. 1, the company saw revenues climb to $454.5 million, up from $401 million a year ago, driven by new instrument systems, including the Acquity H-Class UPLC, UPLC-mass spectrometer solutions, as well as strong TA Instruments product shipments, Douglas Berthiaume, president and CEO of Waters, said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.